BRCA1 and cancer: PARPi are particularly active in cancers which have an impaired ability to repair double-strand DNA breaks (DSBs) via the homologous recombination (HR) pathway.5 HR deficiency (HRD) occurs as a result of a number of mechanisms most notably through pathogenic mutations, or epigenetic modification, of BRCA1/2.